<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129164</url>
  </required_header>
  <id_info>
    <org_study_id>VIB4920.P2.S2</org_study_id>
    <secondary_id>2019-002713-19</secondary_id>
    <nct_id>NCT04129164</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome</brief_title>
  <acronym>SS</acronym>
  <official_title>A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viela Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viela Bio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920&#xD;
      (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enrol 2 SS populations: Population 1 will include participants with moderate&#xD;
      to high systemic disease activity defined by European League Against Rheumatism (EULAR)&#xD;
      Sjögren's Syndrome Disease Activity Index (ESSDAI) &gt;= 5; Population 2 will include&#xD;
      participants with moderate to severe subjective symptoms defined by EULAR Sjögren's Syndrome&#xD;
      Patient Reported Index (ESSPRI) score &gt;= 5 and residual stimulated salivary flow but with&#xD;
      mild systemic disease activity defined by ESSDAI score &lt; 5. This study will include 3&#xD;
      periods: screening (4 weeks), treatment period (40 Weeks) and follow-up period (12 weeks). In&#xD;
      the treatment period, participants from each of the populations will be randomized at 1:1&#xD;
      ratio to receive intravenous (IV) dose of VIB4920 or placebo (Stage I). After completion of&#xD;
      Stage I, participants randomized to VIB4920 in Stage I will receive placebo and participants&#xD;
      randomized to placebo in Stage I will receive VIB4920 (Stage II). Participants who had study&#xD;
      drug discontinuation will not be eligible for treatment during Stage II. All participants&#xD;
      will be followed for at least 12 weeks after their last dose of study drug administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">June 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 18, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) at Day 169 in Population 1</measure>
    <time_frame>Baseline (Day 1) and Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) at Day 169 in Population 2</measure>
    <time_frame>Baseline (Day 1) and Day 169</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ESSPRI at Day 169 in Population 1</measure>
    <time_frame>Baseline (Day 1) and Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants achieving ESSDAI [3] and ESSDAI [4] response in Population 1</measure>
    <time_frame>Baseline (Day 1) to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants achieving ESSPRI response in Population 2</measure>
    <time_frame>Baseline (Day 1) to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Score at Day 169 in Populations 1 and 2</measure>
    <time_frame>Baseline (Day 1) and Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169 in Populations 1 and 2</measure>
    <time_frame>Baseline (Day 1) and Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Severity at Day 169 in Populations 1 and 2</measure>
    <time_frame>Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Populations 1 and 2</measure>
    <time_frame>From Baseline (Day 1) up to Day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants With Adverse Events of Special Interest (AESIs) in Populations 1 and 2</measure>
    <time_frame>From Baseline (Day 1) up to Day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Parameters, Vital Signs, and Electrocardiograms (ECGs) Reported as TEAEs in Populations 1 and 2</measure>
    <time_frame>From Baseline (Day 1) up to Day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of VIB4920</measure>
    <time_frame>Day 1 to Day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Antibody Titer to VIB4920 in Populations 1 and 2</measure>
    <time_frame>Day 1 to Day 365</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>VIB4920 Dose 1 in Population 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Population 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIB4920 Dose 1 in Population 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Population 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIB4920</intervention_name>
    <description>Intravenous Dose 1.</description>
    <arm_group_label>Placebo in Population 1</arm_group_label>
    <arm_group_label>Placebo in Population 2</arm_group_label>
    <arm_group_label>VIB4920 Dose 1 in Population 1</arm_group_label>
    <arm_group_label>VIB4920 Dose 1 in Population 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous dose matched to VIB4920.</description>
    <arm_group_label>Placebo in Population 1</arm_group_label>
    <arm_group_label>Placebo in Population 2</arm_group_label>
    <arm_group_label>VIB4920 Dose 1 in Population 1</arm_group_label>
    <arm_group_label>VIB4920 Dose 1 in Population 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with SS by meeting the 2016 American College of Rheumatology (ACR)/EULAR&#xD;
             Classification Criteria.&#xD;
&#xD;
          -  Residual salivary gland function as defined by whole stimulated salivary flow &gt; 0.1&#xD;
             mL/min (only for Population 2).&#xD;
&#xD;
          -  Have an ESSDAI score of &gt;= 5 at screening; (not including the peripheral nervous&#xD;
             system, central nervous system, and pulmonary domains) (only for Population 1).&#xD;
&#xD;
          -  Have an ESSPRI score of &gt;= 5 at screening (only for Population 2).&#xD;
&#xD;
          -  Have an ESSDAI score of &lt; 5 at screening (only for Population 2).&#xD;
&#xD;
          -  Positive for either anti-Ro autoantibodies or rheumatoid factor, or both at screening.&#xD;
&#xD;
          -  Male and female participants who agree to follow protocol defined contraceptive&#xD;
             methods.&#xD;
&#xD;
          -  No active or untreated latent tuberculosis (TB).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history of confirmed deep venous thrombosis or arterial thromboembolism within&#xD;
             2 years of signing the informed consent form (ICF).&#xD;
&#xD;
          -  Risk factors for venous thromboembolism or arterial thrombosis, prothrombotic status.&#xD;
&#xD;
          -  Concomitant polymyositis or dermatomyositis or systemic sclerosis.&#xD;
&#xD;
          -  Active malignancy or history of malignancy, except in situ carcinoma of the cervix and&#xD;
             cutaneous basal cell carcinoma.&#xD;
&#xD;
          -  Hepatitis B, hepatitis C, or human immunodeficiency virus infection.&#xD;
&#xD;
          -  More than one episode of herpes zoster and/or an opportunistic infection in the last&#xD;
             12 months.&#xD;
&#xD;
          -  Active viral, bacterial, or other infections or history of more than 2 infections&#xD;
             requiring intravenous antibiotics within 12 months prior to signing the ICF.&#xD;
&#xD;
          -  Participants with corona virus disease 2019 (COVID-19) infection or who, in the&#xD;
             judgment of the investigator, are at unacceptable risk of COVID-19 or its&#xD;
             complications.&#xD;
&#xD;
          -  A documented positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)&#xD;
             test within 2 weeks prior to randomization.&#xD;
&#xD;
          -  Received live (attenuated) vaccine within the 4 weeks prior to ICF signature.&#xD;
&#xD;
          -  Treated with any biologic B-cell-depleting therapy within 12 months or other B-cell&#xD;
             targeting therapy &lt; 3 months before randomization.&#xD;
&#xD;
          -  Injectable corticosteroids (including intraarticular) or treatment with &gt; 10 mg/day&#xD;
             dose oral prednisone or equivalent within 6 weeks prior to randomization (only for&#xD;
             Population 1).&#xD;
&#xD;
          -  Treated with systemic corticosteroids for indications other than SS, rheumatoid&#xD;
             arthritis (RA), and systemic lupus erythematosus (SLE) for more than a total of 2&#xD;
             weeks within 24 weeks prior to screening visit (only for Population 1).&#xD;
&#xD;
          -  Received previous treatment with anti-CD40L compounds at any time before screening.&#xD;
&#xD;
          -  Pregnant or lactating or planning to get pregnant during the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>1-866-479-6742</phone>
    <email>ClinicalTrials@VielaBio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <zip>5000003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411013</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharshtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <state>Lambardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brescia</city>
        <state>Province Of Brescia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon si</city>
        <state>Gyeonggi</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <state>Republic Of Korea</state>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <state>Republic Of Korea</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <state>Republic Of Korea</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saltillo</city>
        <state>Coahuila</state>
        <zip>25000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de mexico</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <state>San Martin De Porres</state>
        <zip>31</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>1</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>33</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-363</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-412</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siedlce</city>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Truro</city>
        <zip>TR13LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sjögren's Syndrome</keyword>
  <keyword>SS</keyword>
  <keyword>VIB4920</keyword>
  <keyword>MEDI4920</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

